B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy
- Authors
- Kim, SJ[Kim, Seok Jin]; Won, JH[Won, Jong Ho]
- Issue Date
- Jan-2012
- Publisher
- INFORMA HEALTHCARE
- Keywords
- Rituximab; chronic GVHD; allogeneic stem cell tran
- Citation
- LEUKEMIA & LYMPHOMA, v.53, no.1, pp.19 - 25
- Indexed
- SCIE
SCOPUS
- Journal Title
- LEUKEMIA & LYMPHOMA
- Volume
- 53
- Number
- 1
- Start Page
- 19
- End Page
- 25
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/66739
- DOI
- 10.3109/10428194.2011.603448
- ISSN
- 1042-8194
- Abstract
- Chronic graft-versus-host disease (GVHD) is a serious complication that develops frequently in survivors of allogeneic stem cell transplant. Since elucidation of the role of B cells in the pathogenesis of chronic GVHD, B cell-depleting therapy with rituximab has been associated with beneficial effects in clinical and laboratory studies in patients with chronic GVHD. Although the mechanism underlying the contribution of B cells to the development of chronic GVHD is poorly understood, recent studies have proposed that B cell reconstitution after allogeneic stem cell transplant is involved in the development of chronic GVHD. Inadequate reconstitution of naive B cells and the persistence of high levels of B cell-activating factor have been found in patients with chronic GVHD, and these changes might be associated with the expansion of activated CD27-positive B cells that produce autoantibody in chronic GVHD. In the light of this altered B cell homeostasis in chronic GVHD, the role of rituximab in controlling the clinical manifestations of chronic GVHD has been studied. In this review, we address the role of B cells in the pathogenesis of chronic GVHD and the response to B cell-depleting therapy based on B cell homeostasis.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.